<DOC>
	<DOC>NCT00421018</DOC>
	<brief_summary>The purpose of this study is to determine whether use of exhaled NO (nitric oxide) to regulate the anti-inflammatory treatment leads to increased asthma-related quality of life in patients with allergic asthma</brief_summary>
	<brief_title>Optimization of Asthma Treatment Through Exhaled NO for Increased Asthma-Related Quality of Life (NOAK)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>Age 1864 Clinical diagnosis of Asthma Glucocorticoid treatment &gt; 6 months. Verified Allergy Read and speak Swedish Smoking Current regular treatment with longacting beta2agonist Treatment with Singulair only or in combination with glucocorticoids Taking part in other research study Pregnancy or breastfeeding Unstable Asthma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Allergy</keyword>
	<keyword>Cytokines</keyword>
	<keyword>Glucocorticoids</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Nitric Oxide (NO)</keyword>
	<keyword>Quality of Life</keyword>
	<keyword>Self-Rated Health</keyword>
	<keyword>Stress</keyword>
</DOC>